Investors & Media

Press Releases

Press Releases

Date Title View
Toggle Summary Sage Therapeutics Appoints Chris Benecchi as Chief Commercial Officer
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 21, 2021-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced the appointment of Chris Benecchi
View HTML
Toggle Summary Sage Therapeutics Receives Fast Track Designation for SAGE-718 for the Treatment of Huntington’s Disease
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 15, 2021-- Sage Therapeutics, Inc. (Nasdaq:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the U.S.
View HTML
Toggle Summary Sage Therapeutics to Present at the Morgan Stanley Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 2, 2021-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will
View HTML
Toggle Summary Sage Therapeutics to Present at Upcoming August Investor Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 4, 2021-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will present
View HTML
Toggle Summary Sage Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
Announced positive topline data from pivotal WATERFALL Study of zuranolone in patients with MDD showing statistically significant and clinically meaningful reduction in depressive symptoms at Day 15, primary endpoint Continued pipeline expansion and acceleration advancing all three brain health
View HTML
Toggle Summary Sage Therapeutics to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 20, 2021-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast
View HTML
Toggle Summary Sage Therapeutics to Participate in Cowen’s Psychedelics & Novel Mechanisms in Neuropsychiatry Summit
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 8, 2021-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will
View HTML
Toggle Summary Sage Therapeutics to Participate in SVB Leerink’s 3rd Annual CNS Forum
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 24, 2021-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will
View HTML
Toggle Summary Sage Therapeutics to Host Conference Call
Announcing Positive Phase 3 Results for Zuranolone, an Investigational Two-Week, Once Daily Therapeutic Being Evaluated for Major Depressive Disorder Webcast scheduled for 8:00a.m. ET on Tuesday, June 15 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 15, 2021-- Sage Therapeutics (Nasdaq: SAGE), a
View HTML
Toggle Summary Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder
At the Day 15 primary endpoint, zuranolone 50 mg showed a statistically significant and clinically meaningful reduction in depressive symptoms as measured by HAMD-17 (p=0.0141) compared to placebo Rapid onset of treatment effect was seen in HAMD-17 results at Days 3, 8, and 12 Patients with a
View HTML